Movement Alert｜DUALITYBIO-B Rises 5.15% in Regular Trading, Innovative Drug Sector Sentiment Recovery and Breakthrough Therapy Designation Boost Shares

Market Focus08-04

On August 4, DUALITYBIO-B rose 5.15% in regular trading, trading at 190.0 HKD/share, with turnover of HKD 134 million. The stock staged a notable rebound after consecutive declines of 13.7% on July 30 and 5.23% on August 3 driven by GSK competitive pressure.

On the news front, WuXi AppTec reported half-year results that beat expectations and raised full-year guidance across the board, significantly boosting confidence across the innovative drug value chain. The Hong Kong Stock Connect Innovative Drug ETF strengthened broadly, lifting DUALITYBIO-B on sector-wide momentum. Additionally, the company's core pipeline B7-H3 ADC Elfe-D recently received NMPA breakthrough therapy designation, securing regulatory recognition both domestically and internationally. Multiple brokerages have issued Buy ratings, with fundamental support gradually restoring market confidence.

Within the Biotechnology sector, among individual stocks, INNOVENT BIO up 0.64%, AKESO up 2.01%, BEONE MEDICINES up 0.84%, TRANSTHERA-B up 12.3%, 3SBIO up 1.7%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195515429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 13:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195515429","market":"us","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.15% in Regular Trading, Innovative Drug Sector Sentiment Recovery and Breakthrough Therapy Designation Boost Shares","media":"Market Focus","content":"<p><p>On August 4, DUALITYBIO-B rose 5.15% in regular trading, trading at 190.0 HKD/share, with turnover of HKD 134 million. The stock staged a notable rebound after consecutive declines of 13.7% on July 30 and 5.23% on August 3 driven by GSK competitive pressure.</p><p>On the news front, WuXi AppTec reported half-year results that beat expectations and raised full-year guidance across the board, significantly boosting confidence across the innovative drug value chain. The Hong Kong Stock Connect Innovative Drug ETF strengthened broadly, lifting DUALITYBIO-B on sector-wide momentum. Additionally, the company's core pipeline B7-H3 ADC Elfe-D recently received NMPA breakthrough therapy designation, securing regulatory recognition both domestically and internationally. Multiple brokerages have issued Buy ratings, with fundamental support gradually restoring market confidence.</p><p>Within the Biotechnology sector, among individual stocks, INNOVENT BIO up 0.64%, AKESO up 2.01%, BEONE MEDICINES up 0.84%, TRANSTHERA-B up 12.3%, 3SBIO up 1.7%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.15% in Regular Trading, Innovative Drug Sector Sentiment Recovery and Breakthrough Therapy Designation Boost Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.15% in Regular Trading, Innovative Drug Sector Sentiment Recovery and Breakthrough Therapy Designation Boost Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 13:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, DUALITYBIO-B rose 5.15% in regular trading, trading at 190.0 HKD/share, with turnover of HKD 134 million. The stock staged a notable rebound after consecutive declines of 13.7% on July 30 and 5.23% on August 3 driven by GSK competitive pressure.</p><p>On the news front, WuXi AppTec reported half-year results that beat expectations and raised full-year guidance across the board, significantly boosting confidence across the innovative drug value chain. The Hong Kong Stock Connect Innovative Drug ETF strengthened broadly, lifting DUALITYBIO-B on sector-wide momentum. Additionally, the company's core pipeline B7-H3 ADC Elfe-D recently received NMPA breakthrough therapy designation, securing regulatory recognition both domestically and internationally. Multiple brokerages have issued Buy ratings, with fundamental support gradually restoring market confidence.</p><p>Within the Biotechnology sector, among individual stocks, INNOVENT BIO up 0.64%, AKESO up 2.01%, BEONE MEDICINES up 0.84%, TRANSTHERA-B up 12.3%, 3SBIO up 1.7%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1195515429","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195515429","pubTimestamp":1785821026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, DUALITYBIO-B rose 5.15% in regular trading, trading at 190.0 HKD/share, with turnover of HKD 134 million. The stock staged a notable rebound after consecutive declines of 13.7% on July...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DUALITYBIO-B 常规交易上涨 5.15%，创新药板块情绪复苏和突破性疗法指定提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On August 4, DUALITYBIO-B rose 5.15% in regular trading, trading at 190.0 HKD/share, with turnover of HKD 134 million. The stock staged a notable rebound after consecutive declines of 13.7% on July 30 and 5.23% on August 3 driven by GSK competitive pressure.On the news front, WuXi AppTec reported half-year results that beat expectations and raised full-year guidance across the board, significantly boosting confidence across the innovative drug value chain. The Hong Kong Stock Connect Innovative Drug ETF strengthened broadly, lifting DUALITYBIO-B on sector-wide momentum. Additionally, the company's core pipeline B7-H3 ADC Elfe-D recently received NMPA breakthrough therapy designation, securing regulatory recognition both domestically and internationally. Multiple brokerages have issued Buy ratings, with fundamental support gradually restoring market confidence.Within the Biotechnology sector, among individual stocks, INNOVENT BIO up 0.64%, AKESO up 2.01%, BEONE MEDICINES up 0.84%, TRANSTHERA-B up 12.3%, 3SBIO up 1.7%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195515429","isCrawlerRequest":true}